FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2607412715> ?p ?o ?g. }

• W2607412715 endingPage "1342" @default.
• W2607412715 startingPage "1339" @default.
• W2607412715 abstract "We assessed the potential benefit of treatment for low-risk and high-risk groups in the West of Scotland Coronary Prevention Study (WOSCOPS) population, and compared the benefits of primary and secondary prevention of coronary heart disease (CHD) by lipid lowering with the benefits of blood pressure reduction in the primary prevention of stroke.We did a subgroup analysis of placebo-treated men in the WOSCOPS population by age, vascular disease at trial entry, and other established risk factors. We also compared WOSCOPS findings with those of the Scandinavian Simvastatin Survival Study (4S) and the Medical Research Council (MRC) trial of treatment for mild to moderate hypertension in middle-aged men. The WOSCOPS population comprised 6595 men aged 45-64 years with no history of myocardial infarction (MI) and plasma total cholesterol concentrations of 6.5-8.0 mmol/L at initial screening. Participants were randomly allocated pravastatin (40 mg daily) or placebo, and followed up for an average of 4.9 years.Coronary event rates at 5 years in the WOSCOPS placebo group were higher than 10% (the recommended treatment threshold) in men with pre-existing vascular disease and in those 55 years or older without symptoms or signs of CHD but with at least one other risk factor. Event rates were low in men with hypercholesterolaemia but no other risk factor: 3.5% (95% CI 1.3-5.7) for men aged 45-54 years and 5.3% (2.7-8.0) for men aged 55-64 years. Three times more men had to be treated for 5 years to prevent one endpoint in WOSCOPS than in 4S. By contrast, two to four times fewer men with hyperlipidaemia were treated to save one coronary event in WOSCOPS than hypertensives to save one stroke in the MRC trial. These differences persisted after adjustment for the low-risk status of many of the patients with hypertension who took part in the MRC trial.There were a substantial number of men whose risk of a coronary event was more than 10% at 5 years in the WOSCOPS cohort. The absolute benefit of pravastatin treatment of hyperlipidaemia is less in the primary prevention of CHD than in secondary prevention, but is similar to that for primary prevention of stroke by treatment of mild to moderate hypertension in middle-aged men." @default.
• W2607412715 created "2017-04-28" @default.
• W2607412715 creator A5004626616 @default.
• W2607412715 creator A5010776146 @default.
• W2607412715 creator A5011197091 @default.
• W2607412715 creator A5012748859 @default.
• W2607412715 creator A5015264481 @default.
• W2607412715 creator A5016421285 @default.
• W2607412715 creator A5017846754 @default.
• W2607412715 creator A5021241445 @default.
• W2607412715 creator A5022061427 @default.
• W2607412715 creator A5024616175 @default.
• W2607412715 creator A5030173455 @default.
• W2607412715 creator A5030404726 @default.
• W2607412715 creator A5030607028 @default.
• W2607412715 creator A5032515257 @default.
• W2607412715 creator A5034847182 @default.
• W2607412715 creator A5039255712 @default.
• W2607412715 creator A5039557075 @default.
• W2607412715 creator A5041891332 @default.
• W2607412715 creator A5043329830 @default.
• W2607412715 creator A5047312094 @default.
• W2607412715 creator A5047585339 @default.
• W2607412715 creator A5048047555 @default.
• W2607412715 creator A5049492693 @default.
• W2607412715 creator A5051531865 @default.
• W2607412715 creator A5055824048 @default.
• W2607412715 creator A5058097077 @default.
• W2607412715 creator A5058809258 @default.
• W2607412715 creator A5061749118 @default.
• W2607412715 creator A5062365330 @default.
• W2607412715 creator A5062615215 @default.
• W2607412715 creator A5067740078 @default.
• W2607412715 creator A5069029779 @default.
• W2607412715 creator A5069835205 @default.
• W2607412715 creator A5070811726 @default.
• W2607412715 creator A5075489341 @default.
• W2607412715 creator A5075495901 @default.
• W2607412715 creator A5075866018 @default.
• W2607412715 creator A5076910580 @default.
• W2607412715 creator A5091248520 @default.
• W2607412715 date "1996-11-01" @default.
• W2607412715 modified "2023-10-11" @default.
• W2607412715 title "West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials" @default.
• W2607412715 cites W1965415658 @default.
• W2607412715 cites W2013822143 @default.
• W2607412715 cites W2075950840 @default.
• W2607412715 cites W2111149452 @default.
• W2607412715 cites W2155598961 @default.
• W2607412715 cites W2394957681 @default.
• W2607412715 cites W2608735143 @default.
• W2607412715 cites W4232706911 @default.
• W2607412715 cites W4253422828 @default.
• W2607412715 doi "https://doi.org/10.1016/s0140-6736(96)04292-4" @default.
• W2607412715 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8918276" @default.
• W2607412715 hasPublicationYear "1996" @default.
• W2607412715 type Work @default.
• W2607412715 sameAs 2607412715 @default.
• W2607412715 citedByCount "570" @default.
• W2607412715 countsByYear W26074127152012 @default.
• W2607412715 countsByYear W26074127152013 @default.
• W2607412715 countsByYear W26074127152014 @default.
• W2607412715 countsByYear W26074127152015 @default.
• W2607412715 countsByYear W26074127152016 @default.
• W2607412715 countsByYear W26074127152017 @default.
• W2607412715 countsByYear W26074127152018 @default.
• W2607412715 countsByYear W26074127152019 @default.
• W2607412715 countsByYear W26074127152020 @default.
• W2607412715 countsByYear W26074127152021 @default.
• W2607412715 countsByYear W26074127152022 @default.
• W2607412715 countsByYear W26074127152023 @default.
• W2607412715 crossrefType "journal-article" @default.
• W2607412715 hasAuthorship W2607412715A5004626616 @default.
• W2607412715 hasAuthorship W2607412715A5010776146 @default.
• W2607412715 hasAuthorship W2607412715A5011197091 @default.
• W2607412715 hasAuthorship W2607412715A5012748859 @default.
• W2607412715 hasAuthorship W2607412715A5015264481 @default.
• W2607412715 hasAuthorship W2607412715A5016421285 @default.
• W2607412715 hasAuthorship W2607412715A5017846754 @default.
• W2607412715 hasAuthorship W2607412715A5021241445 @default.
• W2607412715 hasAuthorship W2607412715A5022061427 @default.
• W2607412715 hasAuthorship W2607412715A5024616175 @default.
• W2607412715 hasAuthorship W2607412715A5030173455 @default.
• W2607412715 hasAuthorship W2607412715A5030404726 @default.
• W2607412715 hasAuthorship W2607412715A5030607028 @default.
• W2607412715 hasAuthorship W2607412715A5032515257 @default.
• W2607412715 hasAuthorship W2607412715A5034847182 @default.
• W2607412715 hasAuthorship W2607412715A5039255712 @default.
• W2607412715 hasAuthorship W2607412715A5039557075 @default.
• W2607412715 hasAuthorship W2607412715A5041891332 @default.
• W2607412715 hasAuthorship W2607412715A5043329830 @default.
• W2607412715 hasAuthorship W2607412715A5047312094 @default.
• W2607412715 hasAuthorship W2607412715A5047585339 @default.
• W2607412715 hasAuthorship W2607412715A5048047555 @default.
• W2607412715 hasAuthorship W2607412715A5049492693 @default.
• W2607412715 hasAuthorship W2607412715A5051531865 @default.
• W2607412715 hasAuthorship W2607412715A5055824048 @default.
• W2607412715 hasAuthorship W2607412715A5058097077 @default.

• next